Handelsbanken Fonder
DNTH icon

Handelsbanken Fonder’s Dianthus Therapeutics DNTH Stock Holding History

Handelsbanken Fonder’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49M Buy
+15,300
New +$1.34M ﹤0.01% 947

Other funds holding DNTH

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
PFA
Peak Financial Advisors Denver, Colorado $242M AUM 19.63% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 26.88% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

Handelsbanken Fonder's DNTH Position: Q2 2026 in Review

Handelsbanken Fonder opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 15,300 shares worth $1.49M. The stake represents ﹤0.01% of the portfolio and ranks #947 among its holdings.

12 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Handelsbanken Fonder held 15,300 shares of Dianthus Therapeutics worth $1.49M as of Q2 2026.
  • Dianthus Therapeutics was a new Handelsbanken Fonder position in Q2 2026.
  • Dianthus Therapeutics made up ﹤0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #947 holding.
  • 12 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.